Literature DB >> 21833518

Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic cases.

Steffan W Schulz1, Max Shenin, Amy Mehta, Amal Kebede, Marshall Fluerant, Chris T Derk.   

Abstract

To describe and compare the diagnosis, demographics and management of systemic lupus erythematosus (SLE) related versus idiopathic acute transverse myelitis during the initial presentation of the disease. We undertook a chart review of the hospital records of patients admitted to our hospital from 1994 until 2007 and had the diagnosis of SLE related and idiopathic acute transverse myelitis. Demographics, laboratory and imaging studies, diagnosis and treatment were recorded in both groups and analyzed in a case control fashion. We identified 15 patients with SLE-related acute transverse myelitis (SLE-ATM) and 39 idiopathic (I-ATM) cases between 1994 and 2007. Patients with SLE were more likely to be African American, have CNS demyelinating lesions on MRI, a high IgG% on their CSF analysis and a higher sedimentation rate on presentation. Treatment with high-dose steroids was instituted in both groups of patients, though SLE patients had a longer hospital stay by an average of 5 days. SLE-ATM patients were more likely to be African American as compared to I-ATM patients, have CNS demyelinating lesions on MRI, a high IgG% on CSF analysis and a higher sedimentation rate on presentation. The hospital stay for SLE patients was 5 days longer than the idiopathic patients. This study underlines the importance of early diagnosis of patients who develop ATM related to SLE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21833518     DOI: 10.1007/s00296-011-2053-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  21 in total

1.  Disseminated lupus erythematosus with massive hemorrhagic manifestations and paraplegia.

Authors:  M H WEIL
Journal:  J Lancet       Date:  1955-08

2.  Idiopathic transverse myelitis.

Authors:  Chitra Krishnan; Douglas A Kerr
Journal:  Arch Neurol       Date:  2005-06

3.  Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases.

Authors:  J de Seze; T Stojkovic; G Breteau; C Lucas; U Michon-Pasturel; J Y Gauvrit; E Hachulla; F Mounier-Vehier; J P Pruvo; D Leys; A Destée; P Y Hatron; P Vermersch
Journal:  Brain       Date:  2001-08       Impact factor: 13.501

Review 4.  Transverse myelopathy in SLE: clinical features and functional outcomes.

Authors:  K F Chan; M L Boey
Journal:  Lupus       Date:  1996-08       Impact factor: 2.911

Review 5.  Diagnosis and management of acute myelopathies.

Authors:  Adam I Kaplin; Chitra Krishnan; Deepa M Deshpande; Carlos A Pardo; Douglas A Kerr
Journal:  Neurologist       Date:  2005-01       Impact factor: 1.398

Review 6.  Acute transverse myelopathy complicating systemic lupus erythematosus.

Authors:  D J Propper; R C Bucknall
Journal:  Ann Rheum Dis       Date:  1989-06       Impact factor: 19.103

7.  Longitudinal involvement of the spinal cord in a patient with lupus related transverse myelitis.

Authors:  A A Deodhar; T Hochenedel; R M Bennett
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

8.  Peripheral white matter lesions of the spinal cord with changes in small arachnoid arteries in systemic lupus erythematosus.

Authors:  I Nakano; T Mannen; T Mizutani; R Yokohari
Journal:  Clin Neuropathol       Date:  1989 Mar-Apr       Impact factor: 1.368

9.  Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies.

Authors:  David P D'Cruz; Susana Mellor-Pita; Beatriz Joven; Giovanni Sanna; Judith Allanson; James Taylor; Munther A Khamashta; Graham R V Hughes
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

10.  Prognostic factors of lupus myelopathy.

Authors:  X Lu; Y Gu; Y Wang; S Chen; S Ye
Journal:  Lupus       Date:  2008-04       Impact factor: 2.911

View more
  7 in total

Review 1.  Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica.

Authors:  Corinna Trebst; Peter Raab; Elke Verena Voss; Paulus Rommer; Mazen Abu-Mugheisib; Uwe K Zettl; Martin Stangel
Journal:  Nat Rev Neurol       Date:  2011-11-01       Impact factor: 42.937

2.  Myelitis in systemic lupus erythematosus: clinical features, immunological profile and magnetic resonance imaging of five cases.

Authors:  Javier Pablo Hryb; Edson Chiganer; Edgar Carnero Contentti; José Luis Di Pace; Carmen Lessa; Mónica Beatriz Perassolo
Journal:  Spinal Cord Ser Cases       Date:  2016-07-07

3.  Exploring the risk factors and prognosis of transverse myelitis in systemic lupus erythematosus.

Authors:  Minhui Wang; Ziqian Wang; Li Zhang; Jiuliang Zhao; Di Wu; Jing Li; Qian Wang; Jinmei Su; Dong Xu; Shangzhu Zhang; Mengtao Li; Xiaofeng Zeng
Journal:  Ther Adv Chronic Dis       Date:  2022-05-19       Impact factor: 4.970

Review 4.  Conventional and advanced imaging in neuromyelitis optica.

Authors:  Y Barnett; I J Sutton; M Ghadiri; L Masters; R Zivadinov; M H Barnett
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-13       Impact factor: 3.825

5.  Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis.

Authors:  J N Williams; C B Speyer; D J Kreps; D J Kimbrough; K Costenbader; S Bhattacharyya
Journal:  Lupus       Date:  2019-11-03       Impact factor: 2.911

6.  Suspected Transverse Myelitis with Normal MRI and CSF Findings in a Patient with Lupus: What to Do? A Case Series and Systematic Review.

Authors:  Rory C Monahan; Hannelore J L Beaart; Rolf Fronczek; Gisela M Terwindt; Liesbeth J J Beaart-van de Voorde; Jeroen de Bresser; Margreet Kloppenburg; Nic J A van der Wee; Tom W J Huizinga; Gerda M Steup-Beekman
Journal:  Neuropsychiatr Dis Treat       Date:  2020-12-22       Impact factor: 2.570

Review 7.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.